In a recent interview about President Biden’s recent executive order on artificial intelligence (AI), Morris Panner, the president of Intelerad Medical Systems, shared his concerns that the executive order, while well-intentioned, may wind up stifling innovation and the continued evolution of AI in radiology.
While President Biden’s recently issued executive order on artificial intelligence (AI) emphasizes new standards for the development and use of AI models, Morris Panner has a few reservations and suggests that the executive order may turn out to be “HIPAA for AI” in some respects.
“As well intentioned as HIPAA (Health Insurance Portability and Accountability Act) was, it really shut off a generation of innovation in health care because of what it did to information flow and risk taking in innovation around data,” claimed Panner, the president of Intelerad Medical Systems, in a recent interview.
“I understand why we have HIPAA. We respect HIPAA. We care a lot about patient privacy. But HIPAA was and has continued to be something that most people don’t think really has lived up to its reputation as a portability act. In many ways, the executive order takes some legitimate problems and tries to address them but ends up doing it in a way that will stifle innovation and make it harder for us to take risks at the beginning of the AI innovation cycle.”
(For related content, see “How Will President Biden’s New Executive Order on AI Impact Radiology?,” “Can AI Improve Triage Efficiency in Radiology Workflows for Follow-Up X-Rays?” and “FDA Clears Emerging AI-Enabled Teleradiology Platform.”)
While the executive order references the bolstering of access to technical resources and assistance for smaller companies seeking to develop AI models, Panner suggests the executive order may lead to “a lot of registration and government examination” that would thwart smaller innovative companies and favor more established companies with larger regulatory capabilities but who are also more risk adverse.
For more insights from Morris Panner, watch the video below.
Can CT-Based AI Help Predict Renal Function Decline After Radioligand Therapy for mCRPC?
February 25th 2025In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.
Study Assesses Potential of Seven-Minute AI-Enhanced 3T MRI of the Shoulder
February 20th 2025Researchers found that the use of seven-minute threefold parallel imaging-accelerated deep learning 3T MRI had 89 percent sensitivity for supraspinatus-infraspinatus tendon tears and 93 percent sensitivity for superior labral tears.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.